Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-1167
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-1167 is an investigational small molecule drug developed for the treatment of Alzheimer's disease dementia. It acts as an agonist of the alpha7 nicotinic acetylcholine receptor, a target believed to play a role in cognitive function and memory. The drug is being evaluated as adjunctive therapy to standard acetylcholinesterase inhibitor (AChEI) treatment in people with mild to moderate Alzheimer's disease dementia, with the aim of improving symptoms such as memory and mental activity. Clinical trials are ongoing, with Phase II studies underway across multiple countries. The drug is administered orally, typically as a capsule taken once daily[1][5][6][9].
02
Targets
CHRNA7 (α7 nicotinic receptor)
Beyond the preview
Go deeper on MK-1167.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-1167.